Piscataway, NJ, May 16, 2022–Camber Pharmaceuticals is pleased to announce the addition of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets to their current portfolio.
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 88 lbs.
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets from Camber are available in 600 mg/200 mg/300 mg-30 count bottles.
To find out more about Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets please visit https://www.camberpharma.com
Camber Pharmaceuticals is a fully integrated international pharmaceutical company that maintains quality and integrity in all its products. Its parent company, Hetero Drugs of Hyderabad India, is one of the world’s leading API and finished dosage manufacturers. Camber’s commitment to the consumer is to bring the highest quality generic pharmaceuticals to the market to improve quality of life through cost-effective medications.
# # #
If you would like more information about this topic, please contact Megan Little at [email protected].
